Nicola_K_photos / Shutterstock.com

30 April 2024NewsBiotechnologyLiz Hockley

Amgen and Sandoz settle dispute over blockbuster bone condition drugs

Agreement clears the way for Sandoz to launch denosumab biosimilars in May 2025 | Dispute over multiple patents covering Prolia and Xgeva resolved.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism

19 March 2024 Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details.

Biotechnology

USPTO backs Wands factors post-Amgen enablement loss

11 January 2024 SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions.

More on this story

Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism

19 March 2024 Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details.

Biotechnology

USPTO backs Wands factors post-Amgen enablement loss

11 January 2024 SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions.

More on this story

Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism

19 March 2024 Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details.

Biotechnology

USPTO backs Wands factors post-Amgen enablement loss

11 January 2024 SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent